Trametinib丨CAS 871700-17-3

Trametinib丨CAS 871700-17-3
Product Introduction:
Catalog No.: SS122599
CAS No.: 871700-17-3
Purity (HPLC): 99% min
Product Name: Trametinib
Molecular Formula: C26H23FIN5O4
Molecular Weight: 615.39
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of trametinib丨cas 871700-17-3 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Appearance Off-white Powder
Purity (HPLC) 99% min
1H NMR Consistent to structure

 

Transport Information

 

Parameter

Specification

UN Number

 

Class

 

Packing Group

 

H.S. Code

2933599099304

Stability & Reactivity

The product is chemically stable under standard ambient conditions.

Storage

-20 degC

Condition to Avoid

 

Package

 

 

Manufacturing Information

 

Parameter

Specification

Capacity

 

Frequency

 

Main Export Countries

 

Capacity/Batch

 

Experience

Production since 2015

Stock

 

 

 

 

Applications

 

Trametinib is primarily used as a targeted anticancer pharmaceutical, specifically as a MEK inhibitor in the treatment of melanoma and other cancers with BRAF mutations. It is administered as part of combination therapy or as a monotherapy to inhibit tumor cell proliferation. Additionally, Trametinib is used in preclinical and clinical research to study signal transduction pathways, targeted therapies, and drug resistance mechanisms in oncology.

 

Benefits

 

Trametinib offers highly selective inhibition of MEK1 and MEK2 enzymes, effectively disrupting the MAPK/ERK signaling pathway, which is often overactive in certain cancers. This targeted mechanism allows for reduced tumor growth with potentially fewer off-target effects compared to traditional chemotherapies. Its oral bioavailability and efficacy in combination therapies enhance treatment outcomes and provide a valuable option for patients with specific genetic profiles.

 

Conclusion

 

Trametinib is a critical targeted therapy in oncology, offering selective MEK inhibition for the treatment of cancers driven by BRAF mutations. Its specificity, effectiveness, and clinical versatility make it a key pharmaceutical for modern cancer therapy and ongoing research in targeted anticancer strategies.

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us